Erratum: Evaluation of molecular forms of PSA and human kallikrein 2 in predicting biochemical failure following radical prostatectomy (International Journal of Cancer (2009) 125 (659-663) DOI:10.1002/ijc.23983);Evaluation of molecular forms of prostate-specific antigen and human kallikrein 2 in predicting biochemical failure after radical prostatectomy

International Journal of Cancer

Volumn 124, Issue 3, 2009, Pages 659-663

  Wenske, Sven ^a,b   Korets, Ruslan ^a   Cronin, Angel M ^a   Vickers, Andrew J ^a   Fleisher, Martin ^a   Scher, Howard I ^a   Pettersson, Kim ^c   Guillonneau, Bertrand ^a   Scardino, Peter T ^a   Eastham, James A ^a   Lilja, Hans ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF TURKU   (Finland)

Author keywords

Biochemical recurrence; Free PSA; Human kallikrein 2; Prostate cancer; PSA; Radical prostatectomy

Indexed keywords

KALLIKREIN; KALLIKREIN 2 ENZYME; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG; ISOPROTEIN; TISSUE KALLIKREIN; TUMOR MARKER;

ARTICLE; BLOOD SAMPLING; CLINICAL ASSESSMENT; CONTROLLED STUDY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; AREA UNDER THE CURVE; BLOOD; CASE CONTROL STUDY; PATHOLOGY; PREDICTION AND FORECASTING; PROGNOSIS; PROSTATE TUMOR; ROC CURVE; TUMOR RECURRENCE;

AREA UNDER CURVE; CASE-CONTROL STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; ROC CURVE; TISSUE KALLIKREINS; TUMOR MARKERS, BIOLOGICAL;

EID: 58149294016     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25380     Document Type: Erratum

References (26)

1. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 1998;90:766-71.
2. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997;277:1445-51.
3. Stamey TA, Johnstone IM, McNeal JE, Lu AY, Yemoto CM. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml. J Urol 2002;167:103-11.
4. Rittenhouse HG, Finlay JA, Mikolajczyk SD, Partin AW. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci 1998;35:275-368.
5. Steuber T, Vickers AJ, Haese A, Becker C, Pettersson K, Chun FK, Kattan MW, Eastham JA, Scardino PT, Huland H, Lilja H. Risk assessment for biochemical recurrence prior to radical prostatectomy: significant enhancement contributed by human glandular kallikrein 2 (hK2) and free prostate specific antigen (PSA) in men with moderate PSA-elevation in serum. Int J Cancer 2006;118:1234-40.
6. Steuber T, Niemela P, Haese A, Pettersson K, Erbersdobler A, Felix Chun KH, Graefen M, Kattan MW, Huland H, Lilja H. Association of free-prostate specific antigen subfractions and human glandular kallikrein 2 with volume of benign and malignant prostatic tissue. Prostate 2005;63:13-8.
7. Steuber T, Vickers AJ, Serio AM, Vaisanen V, Haese A, Pettersson K, Eastham JA, Scardino PT, Huland H, Lilja H. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 2007;53:233-40.
8. Greene FL, Page DL, Fleming ID, Fritz A, Balch CM, Haller DG, Morrow M. AJCC Cancer Staging Manual, 5th edn., Philadelphia, PA: Lippincott Raven Publishers, 1997.
9. Sobin LH, Fleming ID. TNM classification of malignant tumors, 5th edn., Union Internationale Contre le Cancer and the American Joint Committee on Cancer. Cancer 1997;80:1803-4.
10. McNeal JE, Redwine EA, Freiha FS, Stamey TA. Zonal distribution of prostatic adenocarcinoma. Correlation with histologic pattern and direction of spread. Am J Surg Pathol 1988;12:897-906.
11. Amling CL, Bergstralh EJ, Blute ML, Slezak JM, Zincke H. Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol 2001;165:1146-51.
12. Mitrunen K, Pettersson K, Piironen T, Bjork T, Lilja H, Lovgren T. Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum. Clin Chem 1995;41:1115-20.
13. Vaisanen V, Eriksson S, Ivaska KK, Lilja H, Nurmi M, Pettersson K. Development of sensitive immunoassays for free and total human glandular kallikrein 2. Clin Chem 2004;50:1607-17.
14. Vaisanen V, Peltola MT, Lilja H, Nurmi M, Pettersson K. Intact free prostate-specific antigen and free and total human glandular kallikrein 2. Elimination of assay interference by enzymatic digestion of antibodies to F(ab′)2 fragments. Anal Chem 2006;78:7809-15.
15. Vaisanen V, Pettersson K, Alanen K, Viitanen T, Nurmi M. Free and total human glandular kallikrein 2 in patients with prostate cancer. Urology 2006;68:219-25.
16. Pepe M. The statistical evaluation of medical tests for classification and prediction. Oxford Statistical Science Series: Oxford University Press, 2003.25.
17. Lilja H, Ulmert D, Bjork T, Becker C, Serio AM, Nilsson JA, Abrahamsson PA, Vickers AJ, Berglund G. Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years. J Clin Oncol 2007;25:431-6.
18. Lilja H. Biology of prostate-specific antigen. Urology 2003;62:27-33.
19. Savblom C, Malm J, Giwercman A, Nilsson JA, Berglund G, Lilja H. Blood levels of free-PSA but not complex-PSA significantly correlates to prostate release of PSA in semen in young men, while blood levels of complex-PSA, but not free-PSA increase with age. Prostate 2005;65:66-72.
20. Aus G, Becker C, Lilja H, Khatami A, Pihl CG, Hugosson J. Free-to-total prostate-specific antigen ratio as a predictor of non-organ-confined prostate cancer (stage pT3). Scand J Urol Nephrol 2003;37:466-70.
21. Becker C, Piironen T, Kiviniemi J, Lilja H, Pettersson K. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem 2000;46:198-206.
22. Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Saeid MS, Young CY, Klee GG, Tindall DJ, Bostwick DG. Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. Urology 1999;53:939-44.
23. Haese A, Graefen M, Becker C, Noldus J, Katz J, Cagiannos I, Kattan M, Scardino PT, Huland E, Huland H, Lilja H. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 2003;54:181-6.
24. Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, Noldus J, Huland H, Lilja H. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 2001;49:101-9.
25. Piironen T, Pettersson K, Suonpaa M, Stenman UH, Oesterling JE, Lovgren T, Lilja H. In vitro stability of free prostate-specific antigen (PSA) and prostate-specific antigen (PSA) complexed to alpha 1-anti-chymotrypsin in blood samples. Urology 1996;48:81-7.
26. Ulmert D, Becker C, Nilsson JA, Piironen T, Bjork T, Hugosson J, Berglund G, Lilja H. Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at - 20 degrees C. Clin Chem 2006;52:235-9.